



Determination of a Differentiation Fate of Monocytes by the TACE Activity
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Abstract：Multiple myeloma (MM) almost exclusively expands in the bone marrow and generates 
devastating bone destruction. We recently reported that GM-CSF and IL-4, an inducer of dendritic cell 
(DC) differentiation, up-regulate TNFα converting enzyme (TACE) expression in monocytes to cleave 
their surface M-CSF receptor (M-CSFR), which drastically disrupts osteoclastogenesis. Because 
TACE activity is inhibited by TIMP3, we explored the expression of TIMP3 and its role in monocyte 
differentiation into osteoclasts and DCs in MM. Bone marrow stromal cells (BMSCs) secreted a large 
amount of TIMP3 protein whose production was further enhanced by IL-6 and TGFβ over-produced 
in MM bone lesions. BMSCs potently suppressed GM-CSF and IL-4-induced DC differentiation 
and resumed osteoclastogenesis from monocytes along with the suppression of surface M-CSFR and 
RANK shedding on monocytes. TIMP3 knockdown in BMSCs by TIMP3 siRNA enhanced M-CSFR 
shedding in monocytes in the presence of BMSCs and resumed GM-CSF and IL-4-mediated DC 
differentiation from monocytes, suggesting monocyte differentiation skewed by BMSC-derived 
TIMP3. These results suggest that TIMP3 over-produced in MM bone marrow microenvironment 
restores surface M-CSFR on monocytes to facilitate their downstream signaling, which causes 
extensive bone destruction and impaired DC differentiation in MM. TIMP3 may therefore become a 
novel target in the treatment of MM bone disease.
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移植が行われている 1, 3, 4）。



































発現する破骨細胞分化因子である Receptor Activator of 
Nuclear Factor Kappa B Ligand（RANKL）とそのおとり




































　破骨細胞はMacrophage Colony Stimulating Factor（M-CSF）
と RANKLにより，樹状細胞は Granulocyte Macrophage 







































































の存在下，非存在下にてヒト CD14+単球を GM-CSFと IL-4で刺激し５日間培養を行った。
（Ｂ）骨髄腫細胞株と骨髄間質細胞による GM-CSFと IL-4誘導性樹状細胞分化抑制に対するM-CSFR 
Fcの効果。
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